Drugs / Oxaloacetic Acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04204889 | Mar 2020 → Aug 2023 | amyotrophic lateral sclerosis | Omar Jawdat | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oxaloacetic Acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04204889 ↗ |
| Route | Oral | “starting with 500mg twice daily orally” NCT04204889 ↗ |